Additionally, the 36-month beta value for ZLAB is 1.15. There are mixed opinions on the stock, with 8 analysts rating it as a “buy,” 3 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for ZLAB is 108.11M and currently, short sellers hold a 7.01% ratio of that float. The average trading volume of ZLAB on March 05, 2025 was 797.43K shares.
ZLAB) stock’s latest price update
The stock price of Zai Lab Limited ADR (NASDAQ: ZLAB) has jumped by 4.65 compared to previous close of 34.00. Despite this, the company has seen a gain of 1.45% in its stock price over the last five trading days. zacks.com reported 2025-03-04 that The consensus price target hints at a 64.4% upside potential for Zai Lab Limited (ZLAB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
ZLAB’s Market Performance
ZLAB’s stock has risen by 1.45% in the past week, with a monthly rise of 29.95% and a quarterly rise of 23.33%. The volatility ratio for the week is 6.97% while the volatility levels for the last 30 days are 5.43% for Zai Lab Limited ADR The simple moving average for the past 20 days is 14.50% for ZLAB’s stock, with a 49.92% simple moving average for the past 200 days.
Analysts’ Opinion of ZLAB
Many brokerage firms have already submitted their reports for ZLAB stocks, with BofA Securities repeating the rating for ZLAB by listing it as a “Neutral.” The predicted price for ZLAB in the upcoming period, according to BofA Securities is $36.10 based on the research report published on March 03, 2025 of the current year 2025.
Morgan Stanley, on the other hand, stated in their research note that they expect to see ZLAB reach a price target of $47.50. The rating they have provided for ZLAB stocks is “Overweight” according to the report published on December 14th, 2023.
Cantor Fitzgerald gave a rating of “Overweight” to ZLAB, setting the target price at $70 in the report published on August 10th of the previous year.
ZLAB Trading at 26.59% from the 50-Day Moving Average
After a stumble in the market that brought ZLAB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -2.79% of loss for the given period.
Volatility was left at 5.43%, however, over the last 30 days, the volatility rate increased by 6.97%, as shares surge +32.50% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +35.64% upper at present.
During the last 5 trading sessions, ZLAB rose by +1.14%, which changed the moving average for the period of 200-days by +70.12% in comparison to the 20-day moving average, which settled at $31.07. In addition, Zai Lab Limited ADR saw 35.85% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ZLAB starting from Edmondson Frazor Titus III, who sale 14,544 shares at the price of $32.98 back on Feb 28 ’25. After this action, Edmondson Frazor Titus III now owns 14,328 shares of Zai Lab Limited ADR, valued at $479,661 using the latest closing price.
Lis William, the Director of Zai Lab Limited ADR, sale 15,000 shares at $32.98 during a trade that took place back on Feb 28 ’25, which means that Lis William is holding 38,089 shares at $494,700 based on the most recent closing price.
Stock Fundamentals for ZLAB
Current profitability levels for the company are sitting at:
- -0.71 for the present operating margin
- 0.63 for the gross margin
The net margin for Zai Lab Limited ADR stands at -0.64. The total capital return value is set at -0.32. Equity return is now at value -31.41, with -23.14 for asset returns.
Based on Zai Lab Limited ADR (ZLAB), the company’s capital structure generated 0.15 points at debt to capital in total, while cash flow to debt ratio is standing at -1.4. The debt to equity ratio resting at 0.18. The interest coverage ratio of the stock is -125.16.
Currently, EBITDA for the company is -242.99 million with net debt to EBITDA at 1.22. When we switch over and look at the enterprise to sales, we see a ratio of 8.9. The receivables turnover for the company is 4.46for trailing twelve months and the total asset turnover is 0.34. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.51.
Conclusion
In conclusion, Zai Lab Limited ADR (ZLAB) has seen better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
